Epithelioid gastrointestinal stromal tumor with PDGFRA activating mutation and immunoreactivity.

Article Details

Citation

Copy to clipboard

Yi ES, Strong CR, Piao Z, Perucho M, Weidner N

Epithelioid gastrointestinal stromal tumor with PDGFRA activating mutation and immunoreactivity.

Appl Immunohistochem Mol Morphol. 2005 Jun;13(2):157-61.

PubMed ID

15894928 [ View in PubMed

]

Abstract

The authors report a unique case of an intra-abdominal, epithelioid mesenchymal tumor that had an activating mutation of PDGFRA and a strong PDGFRA immunoreactivity but lacked both c-kit mutation and c-kit protein (CD117) expression. IHC study showed that the tumor cells were diffusely and strongly positive for PDGFRA, vimentin, CD34, and Bcl-2 but completely negative for CD117 as well as for muscle, epithelial, endothelial, endocrine, mesothelial, neural, and melanocytic cell markers. Molecular study revealed a mutation at the juxtamembrane domain of exon 12 in PDGFRA gene with GTC to GAC transition at codon 561 (V561D), as shown in the previous mutational studies on gastrointestinal stromal tumor (GIST). This case likely represents an example of GIST with PDGFRA activating mutation and PDGFRA immunoreactivity without CD117 positivity, which has not been documented in the literature. STI 571 (imatinib mesylate [Gleevec]) might be an effective therapy in this case, since Gleevec targets both PDGFRA and c-kit oncoproteins.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Imatinib	Platelet-derived growth factor receptor alpha	Protein	Humans	Yes	Antagonist	Details